Z-335 sodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530019

CAS#: 146731-14-8 (sodium)

Description: Z-335 Salt is a thromboxane A2 receptor antagonist potentially for the treatment of arterial occlusive disease.


Price and Availability

Size
Price

Size
Price

Size
Price

Z-335 sodium is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 530019
Name: Z-335 sodium
CAS#: 146731-14-8 (sodium)
Chemical Formula: C18H17ClNNaO4S
Exact Mass:
Molecular Weight: 401.84
Elemental Analysis: C, 53.80; H, 4.26; Cl, 8.82; N, 3.49; Na, 5.72; O, 15.93; S, 7.98


Related CAS #: 146737-36-2 (Free acid)   146731-14-8(sodium)    

Synonym: Z-335; Z335; Z 335

IUPAC/Chemical Name: sodium 2-(2-(((4-chlorophenyl)sulfonamido)methyl)-2,3-dihydro-1H-inden-5-yl)acetate

InChi Key: UEPBEZPJELQKJV-UHFFFAOYSA-M

InChi Code: InChI=1S/C18H18ClNO4S.Na/c19-16-3-5-17(6-4-16)25(23,24)20-11-13-8-14-2-1-12(10-18(21)22)7-15(14)9-13;/h1-7,13,20H,8-11H2,(H,21,22);/q;+1/p-1

SMILES Code: O=C([O-])CC1=CC2=C(CC(CNS(=O)(C3=CC=C(Cl)C=C3)=O)C2)C=C1.[Na+]


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

Related CAS#
146737-36-2(Z-335 Free base)
146731-14-8(Z-335 Salt)


References

1: Yoshida M, Sato Y, Shimura T, Ohkubo S, Honma S, Tanaka T, Kurimoto T, Nakahata N. Distinct effects of z-335, a new thromboxane A2 receptor antagonist, on rabbit platelets and aortic smooth muscle. Pharmacology. 2007;79(1):50-6. PubMed PMID: 17139194.

2: Kawabata Y, Kamada E, Furuta S, Takei M, Kurimoto T, Okudaira K, Nishigaki R. ATP-dependent transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) and its xenobiotic taurine conjugate (Z-335-Tau) by rat bile canalicular membrane vesicles. Pharm Res. 2004 Mar;21(3):467-75. PubMed PMID: 15070098.

3: Matsuno H, Uematsu T, Niwa M, Kozawa O, Nagashima S, Kohno K, Kato H, Kawabata Y, Yoshida Y, Kanamaru M. Pharmacokinetic and pharmacodynamic properties of a new thromboxane receptor antagonist (Z-335) after single and multiple oral administrations to healthy volunteers. J Clin Pharmacol. 2002 Jul;42(7):782-90. PubMed PMID: 12092745.

4: Kawabata Y, Nakamura H, Kamada E, Furuta S, Shinozaki Y, Kurimoto T, Nishigaki R. Mechanism of hepatobiliary transport of a novel thromboxane A2 receptor antagonist, [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335), and its xenobiotic taurine conjugate (Z-335-Tau) in rats. J Pharm Sci. 2003 Jan;92(1):67-76. PubMed PMID: 12486683.

5: Kawabata Y, Furuta S, Shinozaki Y, Kurimoto T, Nishigaki R. Carrier-mediated active transport of a novel thromboxane A(2) receptor antagonist [2-(4-chlorophenylsulfonylaminomethyl)indan-5-yl]acetate (Z-335) into rat liver. Drug Metab Dispos. 2002 May;30(5):498-504. PubMed PMID: 11950778.

6: Tanaka T, Sato R, Kurimoto T. Z-335, a new thromboxane A(2) receptor antagonist, prevents arterial thrombosis induced by ferric chloride in rats. Eur J Pharmacol. 2000 Aug 11;401(3):413-8. PubMed PMID: 10936501.

7: Tanaka T, Fukuta Y, Fukuda Y, Higashino R, Ito S, Takei M, Tamaki H, Kurimoto T, Suzuki Y. Z-335, a thromboxane A2 receptor antagonist, suppresses the progression of arachidonic acid-induced hind limb gangrene in rats. Biol Pharm Bull. 1999 Dec;22(12):1382-4. PubMed PMID: 10746175.

8: Tanaka T, Fukuta Y, Higashino R, Sato R, Nomura Y, Fukuda Y, Ito S, Takei M, Kurimoto T, Tamaki H. Antiplatelet effect of Z-335, a new orally active and long-lasting thromboxane receptor antagonist. Eur J Pharmacol. 1998 Sep 11;357(1):53-60. PubMed PMID: 9788773.

9: Tanaka T, Ito S, Higashino R, Fukuta Y, Fukuda Y, Takei M, Kurimoto T, Tamaki H. A new thromboxane receptor antagonist, Z-335, ameliorates experimental thrombosis without prolonging the rat tail bleeding time. Thromb Res. 1998 Sep 1;91(5):229-35. PubMed PMID: 9755835.

10: Saitoh T, Shibayama T. Removal and degradation of β-lactam antibiotics in water using didodecyldimethylammonium bromide-modified montmorillonite organoclay. J Hazard Mater. 2016 Nov 5;317:677-85. doi: 10.1016/j.jhazmat.2016.06.003. PubMed PMID: 27339949.

11: Wu L, Liu J, Zhang Y, Hou Y. Development of a HPLC/MS/MS method for simultaneous determination of tinidazole, dyclonine and chlorhexidine in rat plasma and its application in the pharmacokinetic research of a film-forming solution. J Pharm Biomed Anal. 2012 Mar 25;62:224-7. doi: 10.1016/j.jpba.2012.01.009. PubMed PMID: 22305084.

12: Shang DW, Wang ZZ, Ni XJ, Zhang M, Hu JQ, Qiu C, Wen YG. Development and validation of a sensitive LC-MS/MS assay for the quantification of nizatidine in human plasma and urine and its application to pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Aug 15;998-999:80-7. doi: 10.1016/j.jchromb.2015.06.026. PubMed PMID: 26197435.

13: Gu W, Wang D, Pan Z, Liu X, Cai B, Chen J. Ultra-performance liquid chromatography-tandem mass spectrometric assay for the simultaneous determination of brucine, strychnine and brucine N-oxide in rat plasma: application to a pharmacokinetic study. Biomed Chromatogr. 2016 Jul;30(7):1097-103. doi: 10.1002/bmc.3656. PubMed PMID: 26578094.

14: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Sep;25(7):565-97. PubMed PMID: 14571286.

15: Li J, Miao F, Lin L, Zhu D, Lin C, Liu J. [Determination of brucine and strychnine in rat after cutaneous administration of semen strychni niosome gel by LC-MS/MS]. Zhongguo Zhong Yao Za Zhi. 2012 Mar;37(6):853-7. Chinese. PubMed PMID: 22715737.

16: Tang Y, Zhang S, Li X, Sun X, Wen N, Yu M, Peng L, Li J, Li Z, Li B. [Determination of mitomycin C in rabbit plasma by ultra-high performance liquid chromatography-tandem mass spectrometry]. Se Pu. 2012 Feb;30(2):154-9. Chinese. PubMed PMID: 22679829.

17: Chen Q, Li P, Li B, Yuan F, Li X, Zhu J. Development of a method for comprehensive and quantitative analysis of armillarisin succinate ester in its medicinal preparations by liquid chromatography-ion trap mass spectrometry. Pharmazie. 2011 Sep;66(9):648-53. PubMed PMID: 22026118.

18: Sun C, Wu J, Wang D, Pan Y. Characterization of a novel impurity in bulk drug eprosartan by ESI/MS(n) and NMR. J Pharm Biomed Anal. 2010 Feb 5;51(3):778-83. doi: 10.1016/j.jpba.2009.09.050. PubMed PMID: 19864105.

19: Xu Y, Si D, Liu C. Determination of strychnine and brucine in rat plasma using liquid chromatography electrospray ionization mass spectrometry. J Pharm Biomed Anal. 2009 Feb 20;49(2):487-91. doi: 10.1016/j.jpba.2008.10.020. PubMed PMID: 19062219.

20: Li L, Pabbisetty D, Carvalho P, Avery MA, Williamson JS, Avery BA. Ultra-performance liquid chromatography-tandem mass spectrometric method for the determination of Artemisinin in rat serum and its application in pharmacokinetics. J Chromatogr B Analyt Technol Biomed Life Sci. 2008 May 1;867(1):131-7. doi: 10.1016/j.jchromb.2008.01.057. PubMed PMID: 18353736.